Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 10064252)


Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.

Vazin A, Davarpanah MA, Ghalesoltani S.

Drug Healthc Patient Saf. 2015 Jun 1;7:97-102. doi: 10.2147/DHPS.S80762. eCollection 2015.


Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.

Abraha I, Cherubini A, Cozzolino F, De Florio R, Luchetta ML, Rimland JM, Folletti I, Marchesi M, Germani A, Orso M, Eusebi P, Montedori A.

BMJ. 2015 May 27;350:h2445. doi: 10.1136/bmj.h2445.


Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis.

Vuichard D, Weisser M, Orasch C, Frei R, Heim D, Passweg JR, Widmer AF.

BMC Infect Dis. 2014 Nov 11;14:573. doi: 10.1186/s12879-014-0573-5.


Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada.

Tahami Monfared AA, O'Sullivan AK, Rotstein C, Papadopoulos G.

Can J Infect Dis Med Microbiol. 2012 Summer;23(2):59-64.


Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy.

Neofytos D, Lu K, Hatfield-Seung A, Blackford A, Marr KA, Treadway S, Ostrander D, Nussenblatt V, Karp J.

Diagn Microbiol Infect Dis. 2013 Feb;75(2):144-9. doi: 10.1016/j.diagmicrobio.2012.10.001. Epub 2012 Nov 8.


Canadian clinical practice guidelines for invasive candidiasis in adults.

Bow EJ, Evans G, Fuller J, Laverdière M, Rotstein C, Rennie R, Shafran SD, Sheppard D, Carle S, Phillips P, Vinh DC.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50.


Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.

Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH.

Korean J Intern Med. 2011 Jun;26(2):220-52. doi: 10.3904/kjim.2011.26.2.220. Epub 2011 Jun 1. Review.


A systematic review of oral fungal infections in patients receiving cancer therapy.

Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D'Amato-Palumbo S, Fischer DJ, Martof A, Nicolatou-Galitis O, Patton LL, Elting LS, Spijkervet FK, Brennan MT; Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO).

Support Care Cancer. 2010 Aug;18(8):985-92. doi: 10.1007/s00520-010-0892-z. Epub 2010 May 8. Review.


Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.

Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J.

Bone Marrow Transplant. 2010 Apr;45(4):662-7. doi: 10.1038/bmt.2009.210. Epub 2009 Aug 17.


Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ.

Haematologica. 2009 Jan;94(1):113-22. doi: 10.3324/haematol.11665. Epub 2008 Dec 9.


Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.

Vehreschild JJ, Böhme A, Reichert D, Kiehl MG, Arenz D, Pankraz K, Kochanek M, Ullmann AJ, Cornely OA.

Int J Hematol. 2008 Mar;87(2):126-31. doi: 10.1007/s12185-008-0045-z. Epub 2008 Feb 21.


Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents.

Due AK, Johansen HK, Gøtzsche PC.

BMC Med Res Methodol. 2006 Aug 14;6:40. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk